Blood Plasma Market Size 2026-2030
The blood plasma market size is valued to increase by USD 20.35 billion, at a CAGR of 9.2% from 2025 to 2030. Rising immunodeficiency and autoimmune disease burden will drive the blood plasma market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 47% growth during the forecast period.
- By Application - Therapeutic use segment was valued at USD 25.92 billion in 2024
- By Source - Human plasma segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 32.51 billion
- Market Future Opportunities: USD 20.35 billion
- CAGR from 2025 to 2030 : 9.2%
Market Summary
- The Blood Plasma Market exhibits robust structural expansion, underpinned by an escalating clinical reliance on advanced biopharmaceutical interventions. Escalating diagnoses of primary immunodeficiency diseases trigger a persistent demand for immunoglobulin products, compelling manufacturers to rapidly expand their source plasma collection capacity to prevent worldwide supply deficits.
- Conversely, fragmented international regulatory frameworks governing ethical donor compensation create significant operational bottlenecks, slowing approval timelines and constraining supply chain fluidity. In practical terms, operating advanced plasma collection networks necessitates precise cold chain logistics to preserve therapeutic integrity.
- Upgrading automated plasmapheresis system technology within donor centers has proven highly effective, reducing average donor procedure times by 20% and improving overall retention rates. The integration of modern chromatographic separation technique ensures higher protein recovery per liter, directly addressing critical shortages of human serum albumin and coagulation factors.
- Strategic localization of biopharmaceutical fractionators in historically underserved regions further accelerates equitable access to life-saving treatments. Ultimately, optimizing these fractionation workflows remains essential for meeting the chronic, non-cyclical dependency on specialized biological preparations.
What will be the Size of the Blood Plasma Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Get Free Sample
How is the Blood Plasma Market Segmented?
The blood plasma industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Application
- Therapeutic use
- Diagnostic use
- Research and development
- Source
- Human plasma
- Synthetic plasma
- Product type
- Immunoglobulins
- Albumin
- Coagulation factors
- Hyperimmune globulins
- Others
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- China
- India
- Japan
- South Korea
- Indonesia
- Thailand
- Rest of World (ROW)
- North America
By Application Insights
The therapeutic use segment is estimated to witness significant growth during the forecast period.
Therapeutic application represents the dominant operational core of the Blood Plasma Market, driven by the escalating necessity for plasma derived therapeutics in managing chronic immunodeficiency and severe neurological conditions.
Clinical adoption of intravenous immunoglobulin therapy and subcutaneous immunoglobulin administration has transformed patient care protocols, significantly altering supply chain demands.
Advanced chromatographic separation technique and continuous purification workflow implementation have enabled biomanufacturers to increase protein purification workflow efficiency by 18%, securing higher yields of critical treatments.
This precise fractionation optimization directly mitigates localized shortages of coagulation factor concentrates and human serum albumin.
By prioritizing targeted immune protection for specialized immune disorders, healthcare networks continuously optimize clinical immunology specialties, accelerating the overall deployment of life-saving interventions while maximizing therapeutic efficacy per liter of processed source material.
The Therapeutic use segment was valued at USD 25.92 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 47% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Blood Plasma Market Demand is Rising in North America Get Free Sample
Regional disparities within the Blood Plasma Market are predominantly shaped by distinct regulatory frameworks and infrastructural maturity.
North America maintains absolute dominance due to its established compensated donor model, operating specialized plasma collection networks that yield 40% higher raw material output compared to Europe.
European initiatives to enhance blood transfusion services through voluntary donations have necessitated substantial investments in pathogen reduction technology, improving regional viral inactivation protocol efficiency by 15%.
In APAC, the rapid modernization of clinical immunology specialties and rising awareness of rare genetic conditions have driven an aggressive expansion of localized contract manufacturing organizations.
The transition from imported therapies to domestic plasma derived medicinal product localization has decreased procurement costs by 20% in emerging economies.
Consequently, strategic investments in plasma cold chain logistics across developing regions continue to bridge historical supply gaps, stabilizing the distribution of essential human serum albumin and targeted immune protection therapies.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The operational landscape of the Blood Plasma Market necessitates meticulous strategic planning to satisfy the escalating clinical requirements for specialized therapeutics. A primary focus for biomanufacturers is plasma fractionation capacity expansion strategy, designed to overcome historical bottlenecks and enhance the output of critical proteins.
- This aligns with the surging subcutaneous immunoglobulin home therapy adoption, which offers greater patient convenience compared to traditional clinical infusions. Establishing a sustainable plasma collection network expansion requires significant capital deployment into modern donor centers, focusing on automated plasmapheresis yield optimization to maximize raw material recovery.
- Furthermore, emerging economies are prioritizing plasma derived medicinal product localization to reduce import dependency, requiring rigorous pathogen reduction in raw plasma to meet international safety mandates. For patients suffering from severe bleeding disorders, ensuring reliable prophylactic treatment for hemophilia patients remains a clinical imperative.
- Emergency medicine is similarly transforming through the introduction of freeze dried plasma for trauma care, eliminating extreme temperature storage constraints and improving field deployment capabilities. Modern processing facilities emphasize continuous purification in plasma fractionation, increasing throughput and lowering operational overhead by approximately 15% compared to batch-based ethanol methods.
- This structural efficiency secures the steady supply of human serum albumin for critical care and targeted hyperimmune globulin for infectious diseases. Advancements in plasma exchange therapy in neurology further drive baseline demand.
- Maintaining robust cold chain logistics in plasma supply is absolutely vital, coupled with precise chromatographic separation for protein yield and comprehensive donor screening protocols and viral safety, ensuring the continuous delivery of life-saving biological therapies.
What are the key market drivers leading to the rise in the adoption of Blood Plasma Industry?
- The rising burden of immunodeficiency and autoimmune diseases serves as the primary catalyst propelling continuous demand across clinical care settings.
- The continuous expansion of the Blood Plasma Market is fundamentally propelled by the escalating diagnosis of severe autoimmune and neurological pathologies.
- Enhanced diagnostic screening protocols for primary immunodeficiency diseases have expanded the confirmed patient base, increasing the routine prescription of intravenous immunoglobulin therapy by 28% across major healthcare networks.
- Simultaneously, the transition toward prophylactic care protocols for congenital bleeding disorders requires a sustained, elevated volume of recombinant clotting factors and plasma-derived concentrates.
- Upgrading automated plasmapheresis system infrastructure has successfully reduced average donor procedure times by 20%, significantly bolstering donor retention and raw material acquisition.
- This persistent clinical dependency generates a non-cyclical demand baseline, compelling biopharmaceutical processors to continuously expand their plasma fractionation process capacity to prevent life-threatening supply deficits in critical care settings.
What are the market trends shaping the Blood Plasma Industry?
- Next generation chromatography and yield technologies represent an emerging trend that is fundamentally reshaping structural growth within the industry landscape.
- The Blood Plasma Market is undergoing a rapid technological evolution, defined by the integration of next-generation processing architectures within industrial fractionation complexes. The transition from traditional ethanol based fractionation toward an advanced continuous purification workflow has revolutionized therapeutic manufacturing. Upgrading legacy systems with a multi-stage depth filtration array has improved usable protein extraction efficiency by 22%, directly addressing supply limitations.
- Concurrently, the implementation of single use processing modules has reduced batch changeover downtime by 35%, significantly optimizing operational overhead for biomanufacturers. This modernization accelerates the processing of raw biological material into high-purity human serum albumin and specialized plasma protein fractions.
- These process engineering innovations allow organizations to maximize the economic value of source plasma collection, securing a resilient, high-volume supply of essential biological therapies.
What challenges does the Blood Plasma Industry face during its growth?
- Stringent regulatory and ethical compliance standards constitute a significant barrier limiting seamless operational expansion throughout the supply chain.
- Operating within the Blood Plasma Market presents formidable structural hurdles due to highly fragmented international compliance frameworks governing ethical donor compensation and biological safety. Disparate regional mandates regarding plasma donor screening and pathogen safety protocols necessitate complex, customized operational strategies.
- The inherent fragility of plasma cold chain logistics dramatically increases supply chain vulnerability, where temperature excursions can elevate raw material spoilage rates by up to 15%. Additionally, establishing modern fractionation facilities requires immense capital expenditure, inflating the final cost of specialized hyperimmune globulin preparation and targeted therapeutics.
- Navigating these disjointed regulatory landscapes increases compliance verification costs by 18%, significantly straining profit margins for manufacturers attempting to stabilize the distribution of essential plasma derived therapeutics while adhering strictly to localized mandates.
Exclusive Technavio Analysis on Customer Landscape
The blood plasma market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the blood plasma market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Blood Plasma Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, blood plasma market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
ADMA Biologics Inc. - The vendor focuses on developing specialized biotechnological products and specialized plasma protein fractions, delivering critical care and immunological therapies through an integrated biomanufacturing and donor collection network.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- ADMA Biologics Inc.
- Bharat Serums and Vaccines Ltd.
- BioIVT LLC
- Biotest AG
- CSL Behring
- Evolve Biologics Inc.
- GC Biopharma Corp.
- Grifols SA
- Kamada Ltd.
- Kedrion SpA
- KM Biologics Co. Ltd.
- LFB SA
- Meiji Holdings Co. Ltd.
- Octapharma AG
- PlasmaGen BioSciences Pvt. Ltd.
- Prothya Biosolutions
- SK Plasma Co. Ltd.
- Takeda Pharmaceutical Ltd.
- Terumo Corp.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Blood plasma market
- In the Pharmaceuticals industry, the rapid deployment of modular single use modules has reduced facility changeover times by up to 40%, directly enhancing fractionation yield optimization for plasma derived therapeutics.
- The implementation of stringent advanced pathogen reduction mandates by health authorities has compelled biopharmaceutical fractionators to upgrade viral inactivation protocols, significantly securing plasma cold chain logistics and maintaining therapeutic plasma products availability.
- The transition toward decentralized clinical trials and home-based patient care has increased the adoption of subcutaneous maintenance regimens by 25%, amplifying the sustained demand for high-concentration intravenous immunoglobulin therapy.
- Supply chain localization policies across emerging economies have catalyzed investments in domestic contract manufacturing organizations, expanding local source plasma collection networks and mitigating international plasma logistics disruptions.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Blood Plasma Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 290 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 9.2% |
| Market growth 2026-2030 | USD 20348.5 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 8.7% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, India, Japan, South Korea, Indonesia, Thailand, Brazil, Saudi Arabia, UAE, Turkey, Argentina, Colombia, South Africa and Israel |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The Blood Plasma Market demonstrates persistent resilience as specialized biomanufacturers recalibrate their operational and clinical strategies to address rising chronic disease burdens. At the boardroom level, strategic prioritization of fractionation yield optimization directly influences capital allocation, compliance management, and long-term product viability.
- Implementing an advanced continuous purification workflow alongside a high-precision chromatographic separation technique has allowed commercial processors to increase therapeutic protein recovery by 18%, substantially improving margins and alleviating raw material constraints. This operational upgrade directly supports the expanding deployment of intravenous immunoglobulin therapy and subcutaneous immunoglobulin administration for complex neurological and immunological disorders.
- Furthermore, securing the supply chain demands rigorous adherence to an evolving viral inactivation protocol and pathogen reduction technology, ensuring product integrity across sophisticated plasma cold chain logistics. By expanding automated plasmapheresis system capabilities at source plasma collection facilities, industry leaders guarantee a steady inflow of essential biological material.
- Ultimately, optimizing these core manufacturing processes secures the reliable distribution of crucial coagulation factor concentrates, human serum albumin, and life-saving plasma derived therapeutics.
What are the Key Data Covered in this Blood Plasma Market Research and Growth Report?
-
What is the expected growth of the Blood Plasma Market between 2026 and 2030?
-
USD 20.35 billion, at a CAGR of 9.2%
-
-
What segmentation does the market report cover?
-
The report is segmented by Application (Therapeutic use, Diagnostic use, and Research and development), Source (Human plasma, and Synthetic plasma), Product Type (Immunoglobulins, Albumin, Coagulation factors, Hyperimmune globulins, and Others) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Rising immunodeficiency and autoimmune disease burden, Stringent regulatory and ethical compliance standards
-
-
Who are the major players in the Blood Plasma Market?
-
ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., BioIVT LLC, Biotest AG, CSL Behring, Evolve Biologics Inc., GC Biopharma Corp., Grifols SA, Kamada Ltd., Kedrion SpA, KM Biologics Co. Ltd., LFB SA, Meiji Holdings Co. Ltd., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions, SK Plasma Co. Ltd., Takeda Pharmaceutical Ltd. and Terumo Corp.
-
Market Research Insights
- The Blood Plasma Market continuously adapts to structural healthcare shifts, driven by the escalating prevalence of primary immunodeficiency diseases and autoimmune neuromuscular conditions. Upgrading collection infrastructure with automated scheduling platforms has enhanced donor retention metrics by 22%, directly stabilizing raw material procurement.
- Concurrently, implementing modular single use modules within modern processing facilities has decreased batch transition downtime by 15%, substantially reducing operational overhead for biopharmaceutical fractionators. These supply chain optimizations ensure consistent delivery of specialized therapies, particularly subcutaneous maintenance regimens, which have seen a 30% increase in patient preference due to improved treatment adherence.
- This operational agility reinforces the resilience of plasma collection networks, securing vital therapeutic availability.
We can help! Our analysts can customize this blood plasma market research report to meet your requirements.
RIA - 
